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CASE REPORT
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Abstract
Adrenocortical carcinoma (ACC) is a rare malignancy with an estimated annual incidence of 0.7e2 cases per million.
Most patients present with steroid hormone excess or abdominal mass effects, but 15% of patients with ACC are
diagnosed incidentally. A careful history, physical exam, and pertinent lab investigations are necessary to reach the
diagnosis. Surgical resection is the cornerstone of treatment in localized ACC; however, systemic chemotherapy with
mitotane is preferred in patients with widespread disease or those who are not ideal candidates for surgery.
Keywords: Adrenal cancer, Hypercortisolism, Adrenal mass, Cushingoid adrenal cancer

Introduction

P

hysicians often encounter patients with electrolyte derangements and are tasked with understanding why they occur. The ability to form
many diagnoses that can play a role in such derangements is necessary to treat patients appropriately. We present the case of a patient with severe
hypokalemia secondary to adrenocortical carcinoma
(ACC). ACC is a very high-grade malignancy with a
poor prognosis (1). Patient's can present with signs
of hormone overproduction. However, most of the
time ACC is diagnosed incidentally. Managing ACC
can be a challenge. Localized tumors can be surgically resected, whereas chemotherapy is offered to
patients with metastatic ACC.

1. Case presentation
57-year-old male with past medical history of
schizoaffective disorder and recently diagnosed
hypertension who was brought to the emergency
department after he had a fall and hit his head. On
admission, the patient's vital signs were normal with
a blood pressure of 140/100. Physical exam was
unremarkable. The patient had no family history of
cancer. His baseline labs showed hypokalemia with
a potassium level of 1.8 (3.6e5.2 mmol/L) and
metabolic alkalosis with bicarbonate of 41 (22e29
mEq/L). The patient's home medications included
furosemide and antipsychotics. After admission,
patient suddenly became hypoxic and was requiring
oxygen via nasal cannula. CT scan and MRI
abdomen/pelvis showed a large right adrenal mass
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Fig. 1. CT scan of the abdomen/pelvis showing large right adrenal mass measuring 15.5  9.8 cm in axial dimension. The mass abuts right hepatic
lobe.

Fig. 2. MRI abdomen showing large heterogeneously enhancing mass centered in the region of the right adrenal gland measuring. 16.3 cm cephalocaudal dimension. Mass contains small areas of T1 hyperintense signal suspicious for blood products. Areas of necrosis noted within the mass. Mass
inseparable from and compressing posterior right hepatic lobe and caudate lobe. Signiﬁcant mass effect on the suprarenal IVC as well as extension of
the mass into the intrahepatic IVC lumen.
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Fig. 3. D cells in myxoid stroma consistent with Adrenocortical
carcinoma.

measuring 15.5  9.8 cm in axial dimension and
16.2 cm in cranio-caudal dimension respectively
(Figs. 1 and 2).
Workup for adrenal mass showed aldosterone 7.7
(<23.2 ng/dl), direct renin 9.1 (<33.2 pg/ml) with a
ratio of 0.85, ruling out primary hyperaldosteronism.
His cortisol was 47.8 (6.7e27.60 Ug/dl) and the repeat
was 48 after dexamethasone suppression test was
performed. His ACTH was <1.5 (7.2e63 pg/ml),
pointing towards primary hypercortisolism. Other
signiﬁcant labs ﬁndings included DHEA sulfate of

520 (70e310 ug/dl), 17-hydroxyprogesterone of 310
(27e199 ng/dl) and androstenedione of 103
(40e150 ng/dl). His HbA1C (<6.5%) also jumped up
from 6 to 9 in the last 6 months. Due to the risk of
malignancy, interventional radiology was consulted
to biopsy the adrenal mass. Pheochromocytoma was
ruled out before the biopsy as the plasma metanephrines 28.9 (0e244 pg/dl) and normetanephrine
16.2 (0e88 pg/dl) were within normal limits. Meanwhile, the patient was started on lisinopril and spironolactone, and potassium was repleted as needed.
He was started on insulin regimen for the new onset
diabetes. Biopsy conﬁrmed the diagnosis of adrenal
cortical carcinoma, myxoid variant (Fig. 3). Immunohistochemical staining (Inhibinþ, Melan-Aþ,
Calretinin, Synaptophysinþ) supported an adrenal
cortical phenotype (Fig. 4).
Urology was consulted for surgery but due to the
locally advanced adrenocortical carcinoma with
liver invasion and extension into the inferior vena
cava, the decision was made not to proceed due to
the high risk of morbidity and mortality. The patient
was planned for chemotherapy with mitotane and
was transferred to an adrenal facility for better care.
Patient was eventually lost to follow up.

2. Discussion
Adrenocortical carcinoma (ACC) is a very rare and
aggressive endocrine tumor, with a reported incidence

Fig. 4. Immunohistochemical staining: A-Inhibinþ; B- Calretinin; C-Synaptophysinþ; D- Ki 67.

of 0.5e2 cases per million, occurring more commonly
in women.1 Majority of the cases have already metastasized at the time of diagnosis, most commonly
involving the lymph nodes, lungs, liver and bone. Due
to its aggressive nature, detection at initial stages is
associated with better surgical outcomes. About 60%
of the patients present with symptoms of hormone
excess, which may manifest in the form of Cushing
syndrome, electrolyte abnormalities or virilization,
whereas non-speciﬁc symptoms like abdominal fullness and ﬂank pain may be seen in the rest of the patients
having
non-functioning
tumors.
Hypercortisolism is the most common manifestation
of a functional ACC, which was seen in our patient.
Most patients will have suppressed ACTH and
increased cortisol when checked at 08:00 am. Hypercortisolism is conﬁrmed by a 1 mg dexamethasone
suppression test, midnight salivary cortisol or elevated
24-h free cortisol in urine.2 Other supportive lab
ﬁndings include elevated serum glucose and adrenal
androgens. High urinary vanillylmandelic acid (VMA)
and homovanillic acid (HVA) are also indicative of
ACC. There are various distinct histological morphologies of this tumor, and among these the myxoid
variant is a very rare and aggressive subtype, which
was seen in our patient. The differential diagnoses in
adults include Cushing syndrome, renal cell carcinoma, hyperaldosteronism and hyperandrogenism,3
whereas those in children include nephroblastoma,
neuroblastoma, and metastatic adrenal deposits. Our
patient had an elevated cortisol level with a biopsy
proven adrenocortical carcinoma. Normal plasma
aldosterone to renin ratio (ARR) and normal androgen
levels ruled out primary hyperaldosteronism and
hyperandrogenism, respectively. Approximately 30%
of the ACCs are diagnosed incidentally while scanning
for other medical issues.4 Diagnostic modalities
include biochemical and hormonal tests, imaging
(such as CT, MRI, and FDG-PET scan), and conﬁrmation of diagnosis via histopathology after biopsy.5
Complete surgical excision is the premier treatment
option. Other treatment options entail a multi-disciplinary approach and include mitotane systemic
therapy, cytotoxic chemotherapy, radiation therapy,
radiofrequency ablation, and immunotherapy. Mitotane, by virtue of its adrenolytic activity, reduces local
recurrence and can be used in advanced ACC when
surgery isn't a viable option, and thus was used in the
treatment of our patient.6 The prognosis for ACC is
poor, with 5-year survival rates hovering around
15e44%.7 Older age, functioning tumor, advanced
stage at diagnosis, and incomplete resection are the
main clinical factors associated with poor survival.
Recurrence is frequently seen following a complete
resection. Median time of recurrence is 1 year.
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Surveillance includes CT of the chest and abdomen
every 3 months along with monitoring of steroid hormones.8 Ultrasound has shown clinical signiﬁcance
during follow up of selected patients.9

3. Conclusion
We encountered a rare case of Cushingoid adrenocortical carcinoma. It is very crucial to diagnose it
early, as its poor prognosis and overall survival can
largely be attributed to its aggressive nature and
diagnosis at advanced stages. Complete surgical
resection remains the mainstay of treatment offering
the best chance for long term survival; however,
adjuvant chemotherapy and radiotherapy can be
offered to high-risk patients. Regular follow up
plans should be established due to the high recurrence rate of such tumors.
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